Your browser doesn't support javascript.
loading
Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang, Xiaonan; Selvaraju, Karthik; Saei, Amir Ata; D'Arcy, Padraig; Zubarev, Roman A; Arnér, Elias Sj; Linder, Stig.
Afiliação
  • Zhang X; Department of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden.
  • Selvaraju K; Department of Medical and Health Sciences, Linköping University, SE-581 83, Linköping, Sweden.
  • Saei AA; Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
  • D'Arcy P; Department of Medical and Health Sciences, Linköping University, SE-581 83, Linköping, Sweden.
  • Zubarev RA; Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
  • Arnér ES; Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77, Stockholm, Sweden.
  • Linder S; Department of Oncology-Pathology, Karolinska Institutet, SE-171 76, Stockholm, Sweden; Department of Medical and Health Sciences, Linköping University, SE-581 83, Linköping, Sweden. Electronic address: Stig.Linder@ki.se.
Biochimie ; 162: 46-54, 2019 Jul.
Article em En | MEDLINE | ID: mdl-30946948

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Auranofina / Selenoproteínas / Tiorredoxina Redutase 1 / Tiorredoxina Redutase 2 / Reposicionamento de Medicamentos / Antineoplásicos Limite: Humans Idioma: En Revista: Biochimie Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Auranofina / Selenoproteínas / Tiorredoxina Redutase 1 / Tiorredoxina Redutase 2 / Reposicionamento de Medicamentos / Antineoplásicos Limite: Humans Idioma: En Revista: Biochimie Ano de publicação: 2019 Tipo de documento: Article